AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of adenosine and arbutamine
Number of subjects: 40
Study 11711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of dobutamine and adenosine
Number of subjects: 40
Study 11711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of arbutamine and dobutamine
Number of subjects: 40
Study 9563983 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated social and medical care and case management
Number of subjects: 200
Study 9563983 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional care)
Number of subjects: 200
Study 1857516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 1 mg Gemeprost
Number of subjects: 89
Study 1857516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 6846762 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 30
Study 6846762 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 30
Study 6846762 — intervention group
Group type: EXPERIMENTAL
Intervention: Left 15 degrees tilt position
Number of subjects: 30
Study 6846762 — intervention group
Group type: COMPARATOR
Intervention: Right 15 degrees tilt position
Number of subjects: 30
Study 30793431 — intervention group
Group type: COMPARATOR
Intervention: Elobixibat 10 mg/d
Number of subjects: 0
Study 30793431 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 15 mg/d
Number of subjects: 0
Study 30793431 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat (varied doses 5-15 mg/d)
Number of subjects: 0
Study 30793431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28270028 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Session (HES) administered to the Intervention Group (IG)
Number of subjects: 92
Study 28404657 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 371
Study 28404657 — intervention group
Group type: EXPERIMENTAL
Intervention: DiabetesDriving.com (DD.com)
Number of subjects: 371
Study 23968203 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3(®)
Number of subjects: 17
Study 23968203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21846617 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily in addition to standard treatment
Number of subjects: 36
Study 21846617 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 36
Study 21846617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 19205663 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin orally, followed by 20 mg of simvastatin
Number of subjects: 83
Study 19205663 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 83
Study 17288331 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 60
Study 17288331 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Bond
Number of subjects: 60
Study 17288331 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno IV
Number of subjects: 60
Study 17288331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 60
Study 17288331 — intervention group
Group type: COMPARATOR
Intervention: Control (no adhesive)
Number of subjects: 60
Study 15109523 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery program (MIP)
Number of subjects: 13
Study 15109523 — intervention group
Group type: COMPARATOR
Intervention: Control group (ongoing management)
Number of subjects: 13
Study 11679500 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone antagonist (cetrorelix) at 0.25 mg/day with recombinant FSH 150 IU/day for 21 cycles
Number of subjects: 41
Study 11679500 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH 150 IU/day alone for 27 cycles
Number of subjects: 41
Study 11679500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 41
Study 10204639 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale school-based HIV prevention campaign
Number of subjects: 3866
Study 7977065 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 32
Study 7977065 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg 4 times daily
Number of subjects: 32
Study 2566942 — intervention group
Group type: COMPARATOR
Intervention: Placebo before GHRH
Number of subjects: 7
Study 2566942 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (100 g p.o. 45 min before GHRH)
Number of subjects: 7
Study 2566942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg p.o. 60 min before GHRH)
Number of subjects: 7
Study 2566942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus glucose plus GHRH (administered at ‐60, ‐45 and 0 min)
Number of subjects: 7
Study 50159 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC) 20 mg
Number of subjects: 0
Study 50159 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC) 10 mg
Number of subjects: 0
Study 50159 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31741204 — intervention group
Group type: COMPARATOR
Intervention: In-person MOVE
Number of subjects: 276
Study 31741204 — intervention group
Group type: COMPARATOR
Intervention: WebMOVE
Number of subjects: 276
Study 29934985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial knee pain (MP) induced by hypertonic saline (0.5 mL) injection
Number of subjects: 14
Study 29934985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral knee pain (LP) induced by hypertonic saline injection
Number of subjects: 14
Study 29934985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial knee pain (MP)
Number of subjects: 14
Study 29934985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral knee pain (LP)
Number of subjects: 14
Study 29934985 — intervention group
Group type: COMPARATOR
Intervention: Control group (Isotonic saline injection)
Number of subjects: 14
Study 28669654 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% H2 gas inhalation (1 hour twice a day for 2 weeks)
Number of subjects: 50
Study 28669654 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous medications (for the initial 7 days)
Number of subjects: 50
Study 26670436 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract septal pacing (RVOTs)
Number of subjects: 192
Study 26670436 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apex pacing (RVA)
Number of subjects: 192
Study 26670436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RVOTs and RVA groups
Number of subjects: 192
Study 26670436 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOTs pacing
Number of subjects: 192
Study 23197250 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 20 mg
Number of subjects: 54
Study 23197250 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg plus Ezetimibe 10 mg
Number of subjects: 54
Study 21645439 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA combined with glucocorticoids
Number of subjects: 19
Study 21645439 — intervention group
Group type: COMPARATOR
Intervention: UDCA-monotherapy
Number of subjects: 19
Study 18075220 — intervention group
Group type: COMPARATOR
Intervention: 400 mg/day of plant sterol in 15 g dressing for 4 weeks
Number of subjects: 89
Study 18075220 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day of plant sterol in 15 g dressing for 4 weeks
Number of subjects: 89
Study 18075220 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/day of plant sterol in 15 g dressing for 4 weeks
Number of subjects: 89
Study 18075220 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg/day of plant sterol in 45 g dressing for 4 weeks
Number of subjects: 89
Study 16545905 — intervention group
Group type: EXPERIMENTAL
Intervention: 677T allele in patients with bipolar disorder (BDI)
Number of subjects: 400
Study 16545905 — intervention group
Group type: EXPERIMENTAL
Intervention: 677T allele in patients with schizophrenia
Number of subjects: 400
Study 16545905 — intervention group
Group type: EXPERIMENTAL
Intervention: 677T allele in male patients with bipolar disorder (BDI)
Number of subjects: 400
Study 16545905 — intervention group
Group type: EXPERIMENTAL
Intervention: 677T allele in male patients with schizophrenia
Number of subjects: 400
Study 12872337 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10734658 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) administered during the first days of the induction phase (median: 9 days, range: 2‐27 days)
Number of subjects: 27
Study 10734658 — intervention group
Group type: COMPARATOR
Intervention: No ATRA administration
Number of subjects: 27
Study 9182474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (250 mg per week, preceded by a loading dose of 250 mg/d for 3 days)
Number of subjects: 204
Study 9182474 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg per day)
Number of subjects: 204
Study 9182474 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both drugs
Number of subjects: 204
Study 7584000 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 612
Study 7584000 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed lymph node dissection (DLND)
Number of subjects: 612
Study 7584000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lymph node dissection)
Number of subjects: 612
Study 7584000 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision of primary lesions
Number of subjects: 612
Study 2957520 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration treatment program
Number of subjects: 116
Study 2957520 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment comparison group
Number of subjects: 116
Study 2957520 — intervention group
Group type: EXPERIMENTAL
Intervention: Small treatment dropout group
Number of subjects: 116
Study 31896537 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercise program
Number of subjects: 36
Study 31896537 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 30104309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery using MiniMed Medtronic 670G system
Number of subjects: 0
Study 27018874 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clipping
Number of subjects: 1499
Study 27018874 — intervention group
Group type: COMPARATOR
Intervention: Non-clipping
Number of subjects: 1499
Study 26580872 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Fluorouracil 5% cream (5‐FU) pretreated for 6‐7 days with ALA/PDT
Number of subjects: 30
Study 26580872 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Fluorouracil 5% cream (5‐FU) BID for 6‐7 days without ALA/PDT
Number of subjects: 30
Study 26580872 — intervention group
Group type: EXPERIMENTAL
Intervention: No pretreatment, ALA applied with incubation of 2 hours, illuminated treated areas with 10 J/cm2 with Blu‐U device
Number of subjects: 30
Study 26580872 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU re‐challenge for 6 days after initial treatment
Number of subjects: 30
Study 22961573 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-131 (100 μg s.c.)
Number of subjects: 10
Study 22961573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21237552 — intervention group
Group type: EXPERIMENTAL
Intervention: SimBaby high-fidelity patient simulator
Number of subjects: 20
Study 19544672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate (CAL, 1.2 to 1.8 g/day)
Number of subjects: 20
Study 19544672 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 20
Study 16965203 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 58
Study 16965203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 12888143 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat percutaneous coronary intervention
Number of subjects: 225
Study 12888143 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 225
Study 11111139 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 24
Study 11111139 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 24
Study 9361938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (NEO)
Number of subjects: 101
Study 9361938 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 101
Study 8236070 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (500 micrograms twice a day)
Number of subjects: 12
Study 8236070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3912618 — intervention group
Group type: EXPERIMENTAL
Intervention: T-CAF (Chemotherapy plus Tamoxifen)
Number of subjects: 474
Study 3912618 — intervention group
Group type: COMPARATOR
Intervention: CAF (Chemotherapy only)
Number of subjects: 474
Study 3912618 — intervention group
Group type: COMPARATOR
Intervention: T-CAF and CAF
Number of subjects: 474
Study 31070490 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapatellar nerve block with 5 ml 2% lidocaine
Number of subjects: 34
Study 31070490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 34
Study 29084041 — intervention group
Group type: EXPERIMENTAL
Intervention: booklet/DVD DA
Number of subjects: 34
Study 29084041 — intervention group
Group type: COMPARATOR
Intervention: online DA
Number of subjects: 34
Study 26253006 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CD34+ stem cells (10 to 15 × 10^6 cells/kg)
Number of subjects: 80
Study 26253006 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CD34+ stem cells (4 to 6 × 10^6 cells/kg)
Number of subjects: 80
Study 24458745 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise (PlyEx) training (8 weeks)
Number of subjects: 11
Study 24458745 — intervention group
Group type: EXPERIMENTAL
Intervention: PlyEx (1stPlyEx)
Number of subjects: 11
Study 24458745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no jumping activity)
Number of subjects: 11
Study 23033241 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily
Number of subjects: 133
Study 23033241 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 133
Study 20671063 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease (AD)
Number of subjects: 43
Study 20671063 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic normal pressure hydrocephalus (iNPH)
Number of subjects: 43
Study 20671063 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 18154425 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index diet
Number of subjects: 16
Study 18154425 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic index diet
Number of subjects: 16
Study 15726101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis for Pneumocystis jirovecii pneumonia (PCP)
Number of subjects: 73
Study 15726101 — intervention group
Group type: COMPARATOR
Intervention: High-dose corticosteroid therapy (> or =25 mg prednisolone or > or =4 mg dexamethasone daily for > or =4 weeks)
Number of subjects: 73
Study 12576886 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 26
Study 12576886 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 26
Study 12576886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical approaches
Number of subjects: 26
Study 10588995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 24
Study 10588995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 80 mg twice daily
Number of subjects: 24
Study 10588995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7594041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary saline infusion during excimer laser coronary angioplasty
Number of subjects: 0
Study 7594041 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser irradiation in a blood medium
Number of subjects: 0
Study 1963650 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.6 mg/kg/day for 5 days)
Number of subjects: 7
Study 1963650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 656284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular prednisolone acetate (50 mg and 100 mg)
Number of subjects: 46
Study 656284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular prednisolone analogues (three types)
Number of subjects: 46
Study 29654506 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of Chinese American Community Health Workers (CHWs)
Number of subjects: 43
Study 28705153 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC tablet once daily (Perfect adherence)
Number of subjects: 30
Study 28705153 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC tablet 4 times/week (Moderate adherence)
Number of subjects: 30
Study 28705153 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC tablet 2 times/week (Low adherence)
Number of subjects: 30
Study 25455544 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 358
Study 25455544 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Aortic Valvuloplasty (BAV)
Number of subjects: 358
Study 25455544 — intervention group
Group type: COMPARATOR
Intervention: Medical Management (MM)
Number of subjects: 358
Study 24683783 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam spray
Number of subjects: 30
Study 24683783 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam spray
Number of subjects: 30
Study 21076361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methadone (0.1 mg/kg/dose)
Number of subjects: 78
Study 21076361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methadone (based on weight and fentanyl infusion rate)
Number of subjects: 78
Study 21076361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methadone
Number of subjects: 78
Study 21076361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methadone
Number of subjects: 78
Study 19801052 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily physiotherapy
Number of subjects: 57
Study 19801052 — intervention group
Group type: COMPARATOR
Intervention: Once-daily physiotherapy (Control)
Number of subjects: 57
Study 16454796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedström files
Number of subjects: 60
Study 16454796 — intervention group
Group type: COMPARATOR
Intervention: RaCe rotary instruments
Number of subjects: 60
Study 16454796 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany
Number of subjects: 60
Study 16454796 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha
Number of subjects: 60
Study 14755001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dive exercise (treadmill running at 90% of maximum heart rate for 3 min, followed by 50% for 2 min, repeated eight times for a total of 40 min)
Number of subjects: 12
Study 14755001 — intervention group
Group type: COMPARATOR
Intervention: No pre-dive exercise (control)
Number of subjects: 12
Study 11264335 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide plus interpersonal therapy (IPT)
Number of subjects: 35
Study 11264335 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide and routine clinical management
Number of subjects: 35
Study 9272198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirlindole (150-300 mg daily)
Number of subjects: 116
Study 9272198 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide (300-600 mg daily)
Number of subjects: 116
Study 9272198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirlindole
Number of subjects: 116
Study 9272198 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 116
Study 8100105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 0.5 mg subcutaneously
Number of subjects: 40
Study 8100105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 8100105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 40
Study 8100105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative characteristics
Number of subjects: 40
Study 3555057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for five days
Number of subjects: 76
Study 3555057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 29313753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 eggs per day
Number of subjects: 50
Study 29313753 — intervention group
Group type: COMPARATOR
Intervention: Oatmeal (one packet per day)
Number of subjects: 50
Study 27110573 — intervention group
Group type: EXPERIMENTAL
Intervention: EAAs (8 g/day for 14 days)
Number of subjects: 60
Study 27110573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 60
Study 24065043 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (3 g/day)
Number of subjects: 16
Study 24065043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/day starch flour)
Number of subjects: 16
Study 22583956 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping information (presented with high threat or low threat smoking-related photo)
Number of subjects: 64
Study 22583956 — intervention group
Group type: COMPARATOR
Intervention: High risk information (presented with high threat or low threat smoking-related photo)
Number of subjects: 64
Study 22583956 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping information (presented with low threat photo)
Number of subjects: 64
Study 22583956 — intervention group
Group type: COMPARATOR
Intervention: High risk information (presented with low threat photo)
Number of subjects: 64